WAVE Life Sciences (NASDAQ:WVE) Upgraded to Hold at Wall Street Zen

Key Points

• Wall Street Zen upgraded WAVE Life Sciences from “strong sell” to “hold,” while broader analyst coverage remains more positive, with a consensus “Moderate Buy” rating and an average price target of $20.89.
• WAVE’s latest quarterly results exceeded expectations: revenue reached $13.16 million versus the $4.51 million consensus, and its $0.30 per-share loss was narrower than anticipated. However, analysts still expect a full-year loss, and the company remains deeply unprofitable.
• Shares opened at $3.59, well below the 52-week high of $21.73. Insiders sold 23,564 shares worth $132,476 in the last quarter, while institutional investors and hedge funds owned 89.73% of the stock.

WAVE Life Sciences (NASDAQ:WVE - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "strong sell" rating to a "hold" rating in a report issued on Saturday, Wall Street Zen reports.

WVE has been the subject of several other reports. LADENBURG THALM/SH SH began coverage on WAVE Life Sciences in a research note on Thursday, October 1st. They issued a "buy" rating and a $10.00 price objective for the company. JPMorgan Chase & Co. began coverage on WAVE Life Sciences in a research note on Wednesday, September 23rd. They issued a "neutral" rating on the stock. Zacks Research cut WAVE Life Sciences from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, August 19th. Citigroup dropped their price objective on shares of WAVE Life Sciences from $24.00 to $19.00 and set a "buy" rating on the stock in a research note on Friday, July 31st. Finally, Wedbush set a $13.00 target price on shares of WAVE Life Sciences in a report on Friday, October 2nd. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $20.89.

WAVE Life Sciences Price Performance

Shares of WVE opened at $3.59 on Friday. WAVE Life Sciences has a 12-month low of $3.04 and a 12-month high of $21.73. The business's 50 day moving average is $4.07 and its 200 day moving average is $7.49.

WAVE Life Sciences (NASDAQ:WVE - Get Free Report) last released its earnings results on Tuesday, October 27th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.03. The firm had revenue of $13.16 million for the quarter, compared to the consensus estimate of $4.51 million. WAVE Life Sciences had a negative net margin of 296.86% and a negative return on equity of 44.66%. As a group, sell-side analysts anticipate that WAVE Life Sciences will post -1.09 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Adrian Rawcliffe sold 12,700 shares of the business's stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $5.29, for a total value of $67,183.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Heidi L. Wagner sold 7,000 shares of the company's stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $6.01, for a total value of $42,070.00. Following the transaction, the director directly owned 44,930 shares of the company's stock, valued at approximately $270,029.30. The trade was a 13.48% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 23,564 shares of company stock worth $132,476 in the last quarter. 24.34% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On WAVE Life Sciences

Institutional investors have recently added to or reduced their stakes in the stock. Integrated Wealth Concepts LLC acquired a new position in WAVE Life Sciences during the second quarter worth $180,000. Squarepoint Ops LLC grew its position in shares of WAVE Life Sciences by 68.0% in the second quarter. Squarepoint Ops LLC now owns 2,541,442 shares of the company's stock valued at $14,766,000 after purchasing an additional 1,029,052 shares during the period. Arizona State Retirement System grew its position in shares of WAVE Life Sciences by 17.1% in the second quarter. Arizona State Retirement System now owns 35,826 shares of the company's stock valued at $208,000 after purchasing an additional 5,228 shares during the period. Readystate Asset Management LP acquired a new stake in shares of WAVE Life Sciences in the second quarter valued at about $27,465,000. Finally, AlphaGrep UK Ltd acquired a new stake in shares of WAVE Life Sciences in the second quarter valued at about $78,000. Institutional investors and hedge funds own 89.73% of the company's stock.

Key WAVE Life Sciences News

Here are the key news stories impacting WAVE Life Sciences this week:

• Positive Sentiment: WAVE reported third-quarter revenue of $13.16 million, well above the $4.51 million analyst consensus, while its $0.30 per-share loss was narrower than the expected $0.33 loss. The results helped ease concerns about the company’s financial performance and contributed to a recent share-price rally. Wave Life Sciences stock rallies as Q3 results ease loss fears
• Positive Sentiment: HC Wainwright initiated coverage with a “Strong-Buy” rating, offering a favorable view of WAVE’s long-term prospects. The firm forecasts a $1.09-per-share loss for fiscal 2026 and fiscal 2027, improving to losses of $0.79 in fiscal 2028, $0.68 in fiscal 2029 and $0.47 in fiscal 2030. HC Wainwright stock recommendations
• Neutral Sentiment: HC Wainwright’s quarterly forecasts call for continued losses, ranging from $0.26 to $0.31 per share through the near-term reporting periods. The estimates imply that investors will likely focus on clinical progress, revenue growth and the company’s ability to reduce cash burn rather than near-term profitability.
• Negative Sentiment: Despite beating estimates, WAVE remains deeply unprofitable, with a negative net margin and analyst expectations for another full-year loss. Its shares also remain well below the 52-week high, reflecting continuing execution and biotechnology-sector risks.

About WAVE Life Sciences

WAVE Life Sciences Ltd. NASDAQ: WVE is a biotechnology company focused on developing medicines that act on RNA, a molecule involved in translating genetic information into proteins. The company uses its proprietary chemistry and drug-design technologies to create oligonucleotide therapeutics intended to selectively modify RNA and address the underlying causes of genetic diseases.

Its research programs have included RNA editing and RNA-targeting approaches for conditions such as alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy and other serious genetic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.